TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number and type of reported adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: metabolic phenotype correlation to clinical endpoints
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to First Perceptible Headache Relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean home systolic BP change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety and tolerability of adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Neurological assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of participants without local failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: air leakage after surgery
Endpoint domain: Adverse events/effects
Primary endpoint: the incidence of pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: Urinary Levels of Biomarkers of NNK Metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Efficacy of Analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Penn Shoulder Score (Penn)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of screening tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of MyoStrain to Detect Cardiotoxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of plasma creatinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change of urine output after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cumulative incidence and duration of hemodialysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Quantity of aerosol deposition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total HIV DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD4 Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of the pulmonary forced vital capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: UCP-1 expression in subcutaneous white adipose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: sEMG reduction of masseter muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Early Clinical Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skeletal muscle structure (cross-sectional area)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: best spectacle corrected distant visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of anticoagulant use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: number of good responders without prednisone after 6-months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Calcium cytosol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mitochondrial edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Genomic abnormality spectrum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline atrial natriuretic Peptide (ANP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in WOMAC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: feasibility and safety of semi-continuous intralymphatic vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: modified Rankin Scale ≤3 at 90 days
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Maximum Tolerated Dose (MTD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Public Health Questionnaire-9 depression score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Area Under the Curve [AUC(0-t)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Epigengene score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin involvement measured with modified Rodnan skin score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Skin involvement measured with Raynaud condition score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: MRI assessment of global organ structure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRI assessment of thrombi (R2*)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRI assessment of organ perfusion (Arterial spin labelling [ASL])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma total antioxidant performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemodynamic indicators (PiCCO, ScvO2, O2-delivery)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary analytes (sodium, chloride, CO2 partial pressure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of COPD Exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Cardioendocrine Risk by HOMA 2-IR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Plasma levels of p-cresol sulfate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood Lactate levels in mmol/l
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval (AUC0-24,ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum measured concentration of the analyte in plasma at steady state (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pre-Test Completion
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Post-Test Completion
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in area under the 0-2 hour prandial glucose curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Oswestry Disability Questionnaire (ODQ)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: obstructive apneas per hour of sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Prevalence of aged-related macular degeneration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proximal tubular dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Proximal tubular injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: UPDRS Part II total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UPDRS Part III total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual analogue scale (VAS: 0-100mm)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in residual symptoms of depression (self report)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in residual symptoms of depression (clinician rating)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Change From Baseline for Quantitative Myasthenia Gravis (QMG) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of large vessel ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Osseointegration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IL1b concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Difference in Global Health Status (GHS) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Electromyographic activity of upper arm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hepatic cholate clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30 second chair stand test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cough counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urge to cough
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse health events
Endpoint domain: Adverse events/effects
Primary endpoint: Patients admittance to ICU
Endpoint domain: Mortality/survival
Primary endpoint: Length of total stay at the hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Alleviating the symptoms of COVID-19
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prenylation levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dermatological symptoms (SCORAD score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change of baseline TBUT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Change in Neck and Facial Wrinkles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in FEV1 in % predicted
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Scores on the Alarm Distress Baby (ADBB) assessment scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of participants experiencing adverse events assessed by CTCAE v4.0
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants experiencing adverse events assessed by CTCAE v4.0
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants experiencing clinically significant laboratory abnormalities on Complete Blood Count
Endpoint domain: Adverse events/effects
Primary endpoint: alteration of protein distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Progress towards the goal of therapy for DFU and PI/PU wounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: platelet 5-HT release induced by ADP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: incremental AUC of triglycerides concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in microvascular visceral blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Participants Achieving Sustained Virologic Response 12 Weeks After the End of All Study Therapy (SVR12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Experiencing Adverse Events (AEs) During the Treatment Period and First 14 Follow-up Days
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Discontinuing Study Therapy Due to AEs During the Treatment Period
Endpoint domain: Adverse events/effects
Primary endpoint: Number of referrals for colonoscopies
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of colonoscopy completions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Clinical assessment for sarcopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Delivery of nutrition intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Patients With Pancreatic Fistula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mouth-level exposure (MLE) tar per cigarette
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MLE nicotine per cigarette
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variation in blood glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum level of MDA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: RBC glutathione level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Significant Neurological Impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Significant Cardiac Impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in QT interval corrected for heart rate (QTcF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Negative Resection margin rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Primary Decolonization Efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Persistent Decolonization Efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in the Best Corrected Visual Acuity (BCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: early deterioration or progression rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: WOMAC-Knee
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pharmacokinetic effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median Number of Days to Neutrophil Engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Subjects (%) Who Discontinue the Study Due to an AE
Endpoint domain: Adverse events/effects
Primary endpoint: Suicidality in PD Patients Taking Nabilone
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in Supine and Standing Blood Pressure Measurements (mmHg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of PE/DVT
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of subjects with RVNA concentrations ≥ 0.5 IU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: All Serious Adverse Events (SAEs) and Adverse Events (AEs) leading to subject withdrawal
Endpoint domain: Adverse events/effects
Primary endpoint: Lens Comfort Likert Response
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Accuracy of esophageal and gastric pressure measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of PLA Responders With Target Lesion Clear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of protein markers in detecting early stage pancreatic cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Immune characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Vaginal Cuff Closure Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Readmission (acute)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Fruit and Vegetable Intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in depression ratings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pharmacokinetics (PK) testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under concentration curve of ampicillin/sulbactam and amoxicillin/clavulanic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects With a Treatment Failure
Endpoint domain: Adverse events/effects
Primary endpoint: Variation of plasma IDO activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported loneliness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Median change of electrical activity (qEEG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Enterocolitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: reductions in substance abuse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: retention in drug treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Response rate (complete or partial)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients Screened Positive for One of the Disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oral cancer incidence rate
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants With Normalized Concentrations Of NCC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of ventricular tachyarrhythmias and sudden cardiac death
Endpoint domain: Mortality/survival
Primary endpoint: Alcohol Abstinence Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgical treatment-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma concentration-time curve of total IgG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half-life of total IgG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of infusions with temporally associated adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative risk of Cervical Intraepithelial Neoplasia 2 and 3 (CIN2 and CIN3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Absolute Risk of Cervical Intraepithelial Neoplasia 2 and 3 (CIN2 and CIN3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes of pain location during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of Seizure
Endpoint domain: Adverse events/effects
Primary endpoint: Prevention of premature ovarian failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change of bleeding on probing (BOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Pain Visual Analog Scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Dynamic sitting balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Investigator-assessed progression-free survival (IA-PFS)
Endpoint domain: Mortality/survival
Primary endpoint: QoR-40 global scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in CES-D Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in STAI Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Frequency of intake
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Need of INR monitoring/dose adjustment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Need of bridging
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Anterior chamber cell score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body fluid gain from baseline after 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduced antibiotic use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Intrathecal synthesis of gammaglobulins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Neutrophil Cell Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants That Achieve Complete Wound Closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Reduction in Ulcer Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurocognitive development at age 3 years
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Level of biochemical marker-α- aminoadipicsemialdehyde (AASA) in plasma and urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Six Minutes Walk Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-minutes walking test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes